口服铁麦芽酚治疗肺动脉高压患者铁缺乏
该研究评估口服铁麦芽酚在肺动脉高压合并缺铁性贫血患者中的耐受性和疗效。结果显示口服铁麦芽酚耐受良好且有效,补充铁储备纠正了贫血,并改善右心室功能和运动耐量。
要点
- 口服铁麦芽酚在肺动脉高压合并缺铁性贫血患者中耐受良好且有效。
- 补充铁储备可纠正贫血并改善右心室功能。
- 铁缺乏在肺动脉高压患者中常见,与症状加重和死亡风险增加相关。
核心结论
- 口服铁麦芽酚在肺动脉高压合并缺铁性贫血患者中耐受良好且有效,可纠正贫血并改善右心室功能和运动耐量。
主要发现
- 口服铁麦芽酚耐受良好且有效。
- 补充铁储备纠正了贫血。
- 右心室功能和运动耐量得到改善。
临床怎么用
- 对肺动脉高压合并缺铁性贫血患者,可考虑使用口服铁麦芽酚补铁以纠正贫血并改善右心室功能和运动耐量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral ferric maltol was well tolerated and effective in patients with pulmonary hypertension and iron deficiency anaemia. Restoration of iron stores corrected anaemia and resulted in improved right ventricular function and exercise tolerance https://bit.ly/2zMwvxc Iron deficiency is common in patients with pulmonary hypertension [1, 2]. The underlying pathomechanisms are complex and include impaired iron absorption, elevated hepcidin levels, augmented gastrointestinal loss and reduced availability from the reticuloendothelial system [1, 3, 4]. In patients with pulmonary hypertension, iron deficiency is associated with aggravated symptoms and an increased mortality risk [3, 5].
引用
- Olsson KM, Fuge J, Brod T, et al. Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. Eur Respir J. 2020. PMID: 32444411. doi:10.1183/13993003.00616-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。